You are here



9 June 2011: NorDiag has received a new order from Seegene, South Korea, for 20 Arrow instruments for delivery in Q2 2011.

CEO in NorDiag Mårten Wigstøl: "Seegene purchased 130 instruments in 2010, and many of them late in Q4-10. They have focused on placing these the first 5 months this year. We expect steady purchases from Seegene going forward.

Seegene is using the SeePrep (Arrow) instrument in connection with its assays based on their Seeplex(R) technology covering several viral and bacterial diseases. Seegene has recently launched its Sepsis test using their Seeprep (Arrow)  instrument and Molzym reagents. A successful commercialization of Seegene's sepsis test will be a strong growth and profit driver for NorDiag and strategic partner Molzym.  

In July 2010, NorDiag and the South Korean company Seegene entered into a five-year OEM-agreement for the Seeprep instrument and sample preparation kits. The 5 year OEM agreement has a guaranteed purchase commitment of approximately NOK 30 million with respect to instruments and reagents over the first 2,5 years.
CEO Mårten Wigstøl          Phone: +47 911 65775
About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and reagents) for sample preparation of DNA from difficult biological samples. DNA diagnostics give more rapid and precise answers, and are the fastest growing field within diagnostics. The Company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in Oslo, Norway. The Company has offices and laboratories in Stockholm, Sweden and in Atlanta (GA), USA. The group has today 34.3 man-labour years.

NorDiag is listed on Oslo Stock Exchange with ticker NORD.

For further information -

About Seegene Inc:
Seegene,  Inc. is a  biotechnology company specialized  in molecular diagnostics and research applications. It holds a novel detection platform named "Seeplex(R)," which sets a standard in high-throughput and simultaneous multi-pathogen detection called "multiplexing." Seeplex(R) technology accurately detects multi-pathogens with high-throughput speed, ultimately providing the most economical basis for saving time, labour and cost. Seegene develops, manufactures and markets innovative molecular diagnostic products and services to a worldwide community. Its mission is to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenetics, oncology and chromosomal analyses using innovative proprietary technologies.
Seegene is listed on the Korean stock exchange (KOSDAQ).

Read the notice in Norwegian here